56℃热疗在前列腺癌小鼠模型中经预防性与治疗性免疫方案均诱导肿瘤特异性免疫保护
本研究在TRAMP-C2小鼠前列腺癌移植瘤模型中,测试56℃处理的肿瘤细胞能否在体内诱发了肿瘤特异性记忆免疫应答。56℃处理的TRAMP-C2细胞体外可激活树突状细胞,体内可触发肿瘤特异性细胞毒性T淋巴细胞依赖的免疫应答。单独预防性接种56℃处理的肿瘤细胞可防止肿瘤生长,治疗性方案中联合辅助化疗可控制肿瘤生长。
要点
- 56℃处理肿瘤细胞诱导DAMPs分泌而非细胞表面表达,体外增强树突状细胞活化与CTL交叉致敏。
- 预防性接种56℃处理的TRAMP-C2细胞可产生针对肿瘤生长的保护。
- 治疗性方案中,接种联合辅助化疗可实现肿瘤生长控制。
核心结论
- 56℃处理的TRAMP-C2肿瘤细胞体外可激活树突状细胞,体内可触发肿瘤特异性CTL依赖的免疫应答。
- 单独预防性接种56℃处理的TRAMP-C2肿瘤细胞可提供针对TRAMP-C2肿瘤生长的保护。
- 治疗性方案中,联合辅助化疗可实现肿瘤生长控制。
研究设计与样本
- 在TRAMP-C2小鼠前列腺癌移植瘤模型中开展体内研究,比较预防性与治疗性免疫方案。
主要发现
- 与42-45℃主要促进DAMPs细胞表面表达不同,56℃处理肿瘤细胞诱导DAMPs分泌,体外改善树突状细胞活化与CTL交叉致敏。
- 56℃处理的TRAMP-C2细胞体外可激活树突状细胞,体内可触发肿瘤特异性CTL依赖的免疫应答。
- 预防性接种56℃处理的TRAMP-C2肿瘤细胞可提供针对TRAMP-C2肿瘤生长的保护。
- 治疗性方案中,免疫接种联合辅助化疗可实现肿瘤生长控制。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Most active cancer immunotherapies able to induce a long-lasting protection against tumours are based on the activation of tumour-specific cytotoxic T lymphocytes (CTLs). Cell death by hyperthermia induces apoptosis followed by secondary necrosis, with the production of factors named "danger associated molecular pattern" (DAMP) molecules (DAMPs), that activate dendritic cells (DCs) to perform antigen uptake, processing and presentation, followed by CTLs cross priming. In many published studies, hyperthermia treatment of tumour cells is performed at 42-45 °C; these temperatures mainly promote cell surface expression of DAMPs. Treatment at 56 °C of tumour cells was shown to induce DAMPs secretion rather than their cell surface expression, improving DC activation and CTL cross priming in vitro. Thus we tested the relevance of this finding in vivo on the generation of a tumour-specific memory immune response, in the TRAMP-C2 mouse prostate carcinoma transplantable model. TRAMP-C2 tumour cells treated at 56 °C were able not only to activate DCs in vitro but also to trigger a tumour-specific CTL-dependent immune response in vivo. Prophylactic vaccination with 56 °C-treated TRAMP-C2 tumour cells alone provided protection against TRAMP-C2 tumour growth in vivo, whilst in the therapeutic regimen, control of tumour growth was achieved combining immunization with adjuvant chemotherapy.
引用
- De Sanctis F, Sandri S, Martini M, et al. Hyperthermic treatment at 56 °C induces tumour-specific immune protection in a mouse model of prostate cancer in both prophylactic and therapeutic immunization regimens. Vaccine. 2018. PMID: 29752021. doi:10.1016/j.vaccine.2018.05.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。